<DOC>
	<DOCNO>NCT00047177</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness oxaliplatin treat child recurrent refractory medulloblastoma , supratentorial primitive neuroectodermal atypical teratoid rhabdoid tumor .</brief_summary>
	<brief_title>Oxaliplatin Treating Children With Recurrent Refractory Medulloblastoma , Supratentorial Primitive Neuroectodermal Tumor , Atypical Teratoid Rhabdoid Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Estimate objective response rate oxaliplatin pediatric patient recurrent refractory medulloblastoma first progression . - Estimate objective response rate oxaliplatin pediatric patient recurrent refractory medulloblastoma second later relapse . - Estimate objective response rate oxaliplatin pediatric patient recurrent refractory supratentorial primitive neuroectodermal tumor , atypical teratoid rhabdoid tumor . - Describe pharmacokinetics drug patient . OUTLINE : This multicenter study . Patients stratify accord tumor type ( medulloblastoma [ measurable disease first relapse vs positive cerebrospinal fluid linear leptomeningeal disease v measurable disease second late progression ] vs supratentorial primitive neuroectodermal tumor v atypical teratoid rhabdoid tumor ) . Patients receive oxaliplatin IV 2 hour day 1 . Treatment repeat every 21 day 17 course ( 1 year ) absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 65 patient accrue study within 1.5-2.8 year .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm medulloblastoma , supratentorial primitive neuroectodermal tumor ( include pineoblastomas ependymoblastomas ) , atypical teratoid rhabdoid tumor Recurrent refractory disease Measurable disease radiography Patients positive cerebrospinal fluid cytology linear leptomeningeal disease eligible PATIENT CHARACTERISTICS : Age 21 Performance status Karnofsky 50100 % OR Lansky 50100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 8.0 g/dL ( RBC transfusion allow ) Hepatic Bilirubin great 1.5 time normal ALT le 2.5 time normal Renal Creatinine great 1.5 time normal OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Cardiovascular Shortening fraction least 27 % echocardiogram OR Ejection fraction least 50 % MUGA Pulmonary No dyspnea rest No exercise intolerance Pulse oximetry great 94 % Other No uncontrolled infection No active graftversushost disease No uncontrolled seizure disorder Seizure disorder well control anticonvulsant allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy At least 2 week since prior growth factor At least 6 month since prior allogeneic stem cell transplantation No concurrent colonystimulating factor first course study No concurrent immunomodulating agent Chemotherapy At least 3 week since prior myelosuppressive therapy ( 6 week nitrosoureas ) recover No concurrent anticancer chemotherapy Endocrine therapy If concurrent corticosteroid necessary intracranial pressure , must stable decrease dose least 1 week prior study No concurrent corticosteroid Radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) symptomatic metastatic site At least 3 month since prior craniospinal radiotherapy No concurrent palliative radiotherapy Recovered prior radiotherapy Surgery Not specify Other No concurrent anticancer experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
</DOC>